Last month, an app named Rejoyn became the first FDA-cleared prescription digital therapeutic for patients with major depressive disorder. The app, which changes users’ behavior through various lessons and exercises, was developed by Otsuka Pharmaceutical and Click Therapeutics.

上个月，一款名为Rejoyn的应用程序成为美国食品和药物管理局（FDA）批准的第一款针对重度抑郁症患者的处方数字治疗软件。该应用程序由大冢制药和Click Therapeutics开发，通过各种课程和练习改变用户的行为。

On Monday, Otsuka announced that it is launching a new data and technology-focused subsidiary that will commercialize Rejoyn — as well as other digital therapeutics and connected health products down the line. The new company — named Otsuka Precision Health — is a subsidiary of Otsuka America, which is a subsidiary of Tokyo-based Otsuka Pharmaceutical..

周一，大冢宣布，它将推出一家以数据和技术为重点的新子公司，该子公司将商业化Rejoyn以及其他数字治疗和相关保健产品。这家名为大冢精密健康的新公司是大冢美国的子公司，大冢美国是东京大冢制药的子公司。。

Rejoyn is a six-week program intended to be used alongside antidepressants. The app leverages clinically validated cognitive emotional training to target parts of the brain affected by depression in order to reduce symptoms over time, explained Otsuka Precision Health President Sanket Shah.

Rejoyn是一个为期六周的计划，旨在与抗抑郁药一起使用。Otsuka Precision Health总裁Sanket Shah解释说，该应用程序利用经过临床验证的认知情绪训练来针对受抑郁症影响的大脑部分，以随着时间的推移减轻症状。

Sponsored Post

赞助帖子

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

随着人工智能的兴起，医疗保健领域可能会出现哪些知识产权纠纷？

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Munck Wilson Mandala合伙人格雷格·豪森（GregHowison）在回答电子邮件中提出的问题时，分享了他对人工智能、IP、连接设备及其产生的数据产生的一些法律后果的看法。

Once Rejoyn becomes available to download this summer, people can follow instructions for a virtual consultation. Their prescription will then be filled, and they will receive an access code from a pharmacy, Shah explained. Once they receive the code, they can enter it directly into the app and access the program immediately. .

一旦今年夏天Rejoyn可以下载，人们就可以按照说明进行虚拟咨询。沙阿解释说，他们的处方将被填写，他们将从药房获得访问代码。一旦收到代码，他们就可以直接将其输入应用程序并立即访问程序。。

Shah and the rest of the team at Otsuka Precision Health are currently working to ensure that Rejoyn will be both accessible and affordable for patients  — steps that other digital therapeutics companies often fail to complete, he noted.

沙阿（Shah）和大冢精密医疗（OtsukaPrecision Health）团队的其他成员目前正在努力确保患者既能获得Rejoyn，又能负担得起，他指出，其他数字治疗公司往往无法完成这些步骤。

“Our current focus is bringing Rejoyn to the U.S. market and expanding our patient experience services,” he declared. “We believe in the meaningful role technology can play in the lives of patients to better understand their unique condition and the care teams that surround them through the course of the healthcare experience.

他宣布：“我们目前的重点是将Rejoyn带入美国市场，并扩大我们的患者体验服务。”。“我们相信，技术可以在患者的生活中发挥有意义的作用，从而更好地了解患者的独特状况以及在整个医疗保健过程中围绕他们的护理团队。

Based on that understanding, we are designing our programs to better connect, engage and personalize care wherever possible.”.

基于这种理解，我们正在设计我们的计划，以尽可能更好地连接，参与和个性化护理。”。

From Shah’s point of view, the market has seen an outpaced demand in recent years for alternative therapies and treatments. Patients are seeking ways to overcome common and often-overlooked barriers to care, he pointed out.

从沙阿的角度来看，近年来市场对替代疗法和治疗的需求已经超过了需求。他指出，患者正在寻求克服常见且常被忽视的护理障碍的方法。

presented by

提交人

Sponsored Post

赞助帖子

A Personalized Approach to Medication Nonadherence

个性化的药物不依从性方法

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.

在今年早些时候的Abarca Forward会议上，德勤董事总经理乔治·范安特卫普（GeorgevanAntwerp）讨论了健康的社会决定因素和个性化的会员体验如何改善药物依从性和健康结果。

Better connected treatment plans pose the opportunity to address this need through care that is more personalized and data-driven, Shah added.

沙阿补充说，更好的互联治疗计划为通过更加个性化和数据驱动的护理来满足这一需求提供了机会。

“With Rejoyn’s approval serving as a proof-point for OPH’s capabilities on the market, it is an exciting time for the company to continue pursuing advanced technologies and more precise approaches to revolutionize an industry that needs to acclimate to accelerating change,” he said.

他说：“Rejoyn的批准是OPH在市场上能力的证明，这是该公司继续追求先进技术和更精确方法的激动人心的时刻，以彻底改变一个需要适应加速变化的行业。”。

Photo credit: Zhuyufang, Getty Images

图片来源：朱玉芳、盖蒂影像

Topics

主题

biopharma nl

生物制药

depression treatment

抑郁症治疗

digital therapeutics

数字治疗学

Otsuka

大冢

Otsuka Pharmacecutical

大冢制药

Otsuka Precision Health

大冢精密医疗

Rejoyn

Rejoyn

MedCity News Daily Newsletter

MedCity新闻每日通讯

Sign up and get the latest news in your inbox.

注册并在收件箱中获取最新消息。

Enter your email address

输入您的电子邮件地址

Subscribe Now

立即订阅

We will never sell or share your information without your consent. See our privacy policy.

未经您同意，我们绝不出售或共享您的信息。请参阅我们的隐私政策。